Prognostic impact of inflammatory and nutritional biomarkers in pancreatic cancer

doi:10.5306/wjco.v16.i1.101191

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (477)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

380

Sum=390

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=67

Publishing Process of This Article

Item

Count

Browse

Download

Sum=7

Jan 24, 2025 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Jan 24, 2025; 16(1): 101191
Published online Jan 24, 2025. doi: 10.5306/wjco.v16.i1.101191

Prognostic impact of inflammatory and nutritional biomarkers in pancreatic cancer

Macarena Teja, María I Garrido, Abrahams Ocanto, Felipe Couñago

Macarena Teja, María I Garrido, Abrahams Ocanto, Felipe Couñago, Department of Radiation Oncology, GenesisCare-San Francisco de Asís University Hospital, Madrid 28002, Spain

Macarena Teja, María I Garrido, Abrahams Ocanto, Felipe Couñago, Department of Radiation Oncology, GenesisCare-Vithas La Milagrosa University Hospital, Madrid 28010, Spain

Felipe Couñago, National Director, GenesisCare Spain, Madrid 28043, Spain

Felipe Couñago, Department of Medicine, School of Medicine, Health and Sport, European University of Madrid, Madrid 28670, Spain

Author contributions: Teja M contributed to the discussion and design of the manuscript; Teja M, Garrido MI, Ocanto A and Couñago F contributed to writing and editing the manuscript, review of the literature, and designed the overall concept and outline of the manuscript; All authors contributed to this paper.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Macarena Teja, MD, Attending Doctor, Department of Radiation Oncology, GenesisCare-San Francisco de Asís University Hospital, C/Joaquín Costa 28, Madrid 28002, Spain. macarena.teja@genesiscare.es

Received: September 6, 2024
Revised: September 28, 2024
Accepted: October 10, 2024
Published online: January 24, 2025
Processing time: 53 Days and 18.4 Hours

Core Tip

Core Tip: Nutritional and inflammatory biomarkers are showing promising results in terms of prognosis in oncologic patients. In surgical pancreatic cancer patients, a relationship between some of these markers, post-operative outcomes, relapse-free survival and overall survival have been proven in a recent cohort study. However, there is a lack of standardization of the cut-off values of these biomarkers and there are no comparative trials that determine which marker is the gold standard for pancreatic cancer patients. For these reasons more evidence is needed to introduce them into clinical practice.